 Nikhil Meena
Concepts (233)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 11 | 2025 | 624 | 2.790 |
Why?
| | Shock, Septic | 5 | 2023 | 69 | 2.200 |
Why?
| | Vasopressins | 4 | 2019 | 39 | 2.180 |
Why?
| | Vasoconstrictor Agents | 4 | 2019 | 80 | 2.110 |
Why?
| | Biopsy, Fine-Needle | 6 | 2021 | 104 | 1.870 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 5 | 2023 | 45 | 1.600 |
Why?
| | Norepinephrine | 3 | 2018 | 112 | 1.590 |
Why?
| | Bronchoscopy | 6 | 2025 | 75 | 1.550 |
Why?
| | Dyspnea | 5 | 2022 | 79 | 1.240 |
Why?
| | Pleural Effusion | 3 | 2019 | 38 | 1.140 |
Why?
| | Pleural Effusion, Malignant | 2 | 2017 | 21 | 0.980 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 330 | 0.970 |
Why?
| | Pneumonia | 2 | 2025 | 123 | 0.960 |
Why?
| | Intensive Care Units | 5 | 2019 | 234 | 0.910 |
Why?
| | Aged | 21 | 2025 | 10142 | 0.860 |
Why?
| | Humans | 48 | 2025 | 52114 | 0.850 |
Why?
| | Male | 33 | 2025 | 26652 | 0.840 |
Why?
| | Sensitivity and Specificity | 3 | 2025 | 871 | 0.840 |
Why?
| | Retrospective Studies | 19 | 2025 | 6610 | 0.800 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2025 | 30 | 0.800 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2023 | 101 | 0.790 |
Why?
| | Obesity | 2 | 2025 | 1183 | 0.790 |
Why?
| | Middle Aged | 22 | 2025 | 13028 | 0.760 |
Why?
| | Mycobacterium tuberculosis | 1 | 2023 | 249 | 0.730 |
Why?
| | Body Mass Index | 1 | 2025 | 699 | 0.720 |
Why?
| | Tracheostomy | 2 | 2020 | 76 | 0.710 |
Why?
| | Female | 30 | 2025 | 28055 | 0.710 |
Why?
| | Ticlopidine | 3 | 2016 | 72 | 0.680 |
Why?
| | Nausea | 1 | 2021 | 45 | 0.680 |
Why?
| | Pleurodesis | 2 | 2017 | 8 | 0.670 |
Why?
| | Adult | 19 | 2025 | 14095 | 0.670 |
Why?
| | Vomiting | 1 | 2021 | 71 | 0.660 |
Why?
| | Diarrhea | 1 | 2021 | 95 | 0.660 |
Why?
| | Thoracoscopy | 2 | 2019 | 17 | 0.650 |
Why?
| | Cough | 3 | 2022 | 55 | 0.640 |
Why?
| | Esophagus | 2 | 2017 | 83 | 0.630 |
Why?
| | Time Factors | 4 | 2019 | 2970 | 0.620 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2016 | 211 | 0.620 |
Why?
| | Bronchoscopes | 2 | 2016 | 9 | 0.600 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 29 | 0.600 |
Why?
| | Pleural Diseases | 2 | 2016 | 11 | 0.600 |
Why?
| | Pulmonary Medicine | 2 | 2015 | 14 | 0.600 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2019 | 30 | 0.590 |
Why?
| | Pleura | 2 | 2015 | 13 | 0.580 |
Why?
| | Diagnosis, Differential | 6 | 2022 | 1031 | 0.570 |
Why?
| | Ultrasonography | 2 | 2017 | 420 | 0.570 |
Why?
| | Time-to-Treatment | 1 | 2019 | 77 | 0.560 |
Why?
| | Hypotension | 1 | 2019 | 62 | 0.560 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2018 | 12 | 0.560 |
Why?
| | Respiratory Insufficiency | 3 | 2016 | 115 | 0.560 |
Why?
| | Sclerosing Solutions | 1 | 2017 | 16 | 0.540 |
Why?
| | Granuloma, Foreign-Body | 1 | 2017 | 4 | 0.540 |
Why?
| | Myofibroblasts | 1 | 2018 | 50 | 0.540 |
Why?
| | Bronchial Diseases | 1 | 2017 | 6 | 0.540 |
Why?
| | Confusion | 1 | 2017 | 19 | 0.530 |
Why?
| | Foreign-Body Migration | 1 | 2017 | 30 | 0.530 |
Why?
| | Cryptococcosis | 1 | 2017 | 17 | 0.530 |
Why?
| | Middle Cerebral Artery | 1 | 2017 | 33 | 0.530 |
Why?
| | Ultrasonography, Interventional | 2 | 2015 | 137 | 0.520 |
Why?
| | Referral and Consultation | 1 | 2019 | 288 | 0.520 |
Why?
| | Critical Illness | 5 | 2020 | 310 | 0.520 |
Why?
| | Catheterization | 1 | 2017 | 95 | 0.520 |
Why?
| | Shock, Cardiogenic | 1 | 2017 | 34 | 0.520 |
Why?
| | Mitral Valve | 1 | 2017 | 56 | 0.510 |
Why?
| | Endocarditis, Bacterial | 1 | 2017 | 42 | 0.510 |
Why?
| | Tracheal Neoplasms | 1 | 2016 | 8 | 0.500 |
Why?
| | Pyrethrins | 1 | 2016 | 4 | 0.500 |
Why?
| | Flea Infestations | 1 | 2016 | 4 | 0.500 |
Why?
| | Granular Cell Tumor | 1 | 2016 | 6 | 0.500 |
Why?
| | Pulmonary Eosinophilia | 1 | 2016 | 7 | 0.500 |
Why?
| | Insecticides | 1 | 2016 | 17 | 0.500 |
Why?
| | Midodrine | 1 | 2016 | 6 | 0.500 |
Why?
| | Pulmonary Aspergillosis | 1 | 2016 | 5 | 0.500 |
Why?
| | Lymphoma | 1 | 2017 | 71 | 0.490 |
Why?
| | Cytodiagnosis | 1 | 2015 | 42 | 0.470 |
Why?
| | Superior Vena Cava Syndrome | 1 | 2015 | 10 | 0.470 |
Why?
| | Treatment Outcome | 9 | 2018 | 5456 | 0.470 |
Why?
| | Vascular Access Devices | 1 | 2015 | 22 | 0.470 |
Why?
| | Mediastinal Neoplasms | 1 | 2015 | 18 | 0.470 |
Why?
| | Peptic Ulcer | 1 | 2015 | 14 | 0.470 |
Why?
| | Critical Care | 1 | 2017 | 214 | 0.470 |
Why?
| | Osteochondrodysplasias | 1 | 2015 | 14 | 0.470 |
Why?
| | Tracheal Diseases | 1 | 2015 | 13 | 0.470 |
Why?
| | Gastrointestinal Agents | 1 | 2015 | 39 | 0.460 |
Why?
| | Leukemia, Plasma Cell | 1 | 2015 | 33 | 0.460 |
Why?
| | Trachea | 1 | 2015 | 53 | 0.450 |
Why?
| | Hemorrhage | 1 | 2016 | 222 | 0.450 |
Why?
| | Adrenal Glands | 1 | 2014 | 39 | 0.450 |
Why?
| | Magnesium | 1 | 2014 | 32 | 0.430 |
Why?
| | Myasthenia Gravis | 1 | 2014 | 18 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 4 | 2025 | 1148 | 0.420 |
Why?
| | Plasma Cells | 1 | 2015 | 234 | 0.420 |
Why?
| | Registries | 1 | 2017 | 629 | 0.410 |
Why?
| | Cisplatin | 1 | 2015 | 284 | 0.410 |
Why?
| | Stomach Neoplasms | 1 | 2017 | 194 | 0.410 |
Why?
| | Deglutition Disorders | 1 | 2014 | 76 | 0.400 |
Why?
| | Myocardial Infarction | 1 | 2017 | 445 | 0.390 |
Why?
| | Ovarian Neoplasms | 1 | 2017 | 458 | 0.390 |
Why?
| | Thrombosis | 1 | 2015 | 252 | 0.380 |
Why?
| | Smoking | 1 | 2016 | 516 | 0.380 |
Why?
| | Neoplasms | 1 | 2021 | 1288 | 0.350 |
Why?
| | Internship and Residency | 1 | 2015 | 433 | 0.330 |
Why?
| | Endosonography | 3 | 2023 | 96 | 0.300 |
Why?
| | Breast Neoplasms | 1 | 2017 | 1199 | 0.280 |
Why?
| | Arterial Pressure | 2 | 2018 | 44 | 0.270 |
Why?
| | Organ Dysfunction Scores | 2 | 2017 | 20 | 0.270 |
Why?
| | Sepsis | 2 | 2023 | 229 | 0.270 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 1214 | 0.260 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 374 | 0.250 |
Why?
| | Rare Diseases | 2 | 2018 | 46 | 0.250 |
Why?
| | Incidence | 3 | 2019 | 1070 | 0.250 |
Why?
| | Vancomycin | 2 | 2017 | 86 | 0.240 |
Why?
| | Respiration, Artificial | 2 | 2020 | 290 | 0.240 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 939 | 0.240 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 399 | 0.240 |
Why?
| | Aged, 80 and over | 3 | 2017 | 3382 | 0.230 |
Why?
| | Neoplasm Staging | 2 | 2019 | 766 | 0.220 |
Why?
| | Acute Disease | 2 | 2016 | 386 | 0.220 |
Why?
| | Lymph Nodes | 2 | 2017 | 252 | 0.220 |
Why?
| | Prospective Studies | 3 | 2025 | 2424 | 0.210 |
Why?
| | Ferritins | 2 | 2025 | 36 | 0.210 |
Why?
| | Sputum | 1 | 2023 | 64 | 0.200 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2023 | 29 | 0.200 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2022 | 12 | 0.190 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2022 | 5 | 0.190 |
Why?
| | Dizziness | 1 | 2022 | 13 | 0.190 |
Why?
| | Adenocarcinoma | 2 | 2017 | 401 | 0.190 |
Why?
| | Steroids | 1 | 2021 | 60 | 0.170 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2019 | 23 | 0.160 |
Why?
| | Faculty | 1 | 2020 | 70 | 0.160 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 1665 | 0.160 |
Why?
| | Lost to Follow-Up | 1 | 2019 | 10 | 0.150 |
Why?
| | Echocardiography, Doppler | 1 | 2019 | 55 | 0.150 |
Why?
| | Oncology Service, Hospital | 1 | 2019 | 14 | 0.150 |
Why?
| | Cocaine | 1 | 2019 | 172 | 0.140 |
Why?
| | Hypertension, Pulmonary | 1 | 2019 | 110 | 0.140 |
Why?
| | Pulmonary Artery | 1 | 2019 | 146 | 0.140 |
Why?
| | Communication | 1 | 2020 | 254 | 0.140 |
Why?
| | Social Media | 1 | 2020 | 116 | 0.140 |
Why?
| | Students, Medical | 1 | 2020 | 156 | 0.140 |
Why?
| | Cocaine-Related Disorders | 1 | 2019 | 206 | 0.140 |
Why?
| | Heart Ventricles | 1 | 2019 | 264 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2018 | 147 | 0.130 |
Why?
| | Sutures | 1 | 2017 | 36 | 0.130 |
Why?
| | Catheters, Indwelling | 1 | 2017 | 56 | 0.130 |
Why?
| | Lung Abscess | 1 | 2017 | 5 | 0.130 |
Why?
| | Administration, Intravenous | 1 | 2017 | 73 | 0.130 |
Why?
| | Serratia Infections | 1 | 2017 | 8 | 0.130 |
Why?
| | Etomidate | 1 | 2016 | 5 | 0.130 |
Why?
| | Esophagectomy | 1 | 2017 | 37 | 0.130 |
Why?
| | Drainage | 1 | 2017 | 87 | 0.130 |
Why?
| | Anesthetics, Intravenous | 1 | 2016 | 22 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 796 | 0.130 |
Why?
| | Bronchial Fistula | 1 | 2016 | 5 | 0.130 |
Why?
| | Pneumonia, Ventilator-Associated | 1 | 2016 | 18 | 0.130 |
Why?
| | Device Removal | 1 | 2017 | 82 | 0.130 |
Why?
| | Young Adult | 2 | 2017 | 4307 | 0.130 |
Why?
| | Bronchi | 1 | 2017 | 42 | 0.130 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 11 | 0.130 |
Why?
| | Prostheses and Implants | 1 | 2016 | 54 | 0.130 |
Why?
| | Fatal Outcome | 1 | 2017 | 192 | 0.130 |
Why?
| | Prosthesis Implantation | 1 | 2016 | 48 | 0.120 |
Why?
| | Delivery of Health Care | 1 | 2019 | 318 | 0.120 |
Why?
| | Penicillanic Acid | 1 | 2016 | 21 | 0.120 |
Why?
| | United States | 2 | 2017 | 5168 | 0.120 |
Why?
| | Airway Obstruction | 1 | 2016 | 47 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 482 | 0.120 |
Why?
| | Cephalosporins | 1 | 2016 | 37 | 0.120 |
Why?
| | Esophageal Neoplasms | 1 | 2017 | 110 | 0.120 |
Why?
| | Laser Therapy | 1 | 2016 | 76 | 0.120 |
Why?
| | Recurrence | 1 | 2017 | 680 | 0.120 |
Why?
| | Cost Savings | 1 | 2015 | 58 | 0.120 |
Why?
| | Inservice Training | 1 | 2015 | 30 | 0.120 |
Why?
| | Disease Management | 1 | 2017 | 185 | 0.120 |
Why?
| | Catheters | 1 | 2015 | 34 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 564 | 0.120 |
Why?
| | Pneumothorax | 1 | 2015 | 20 | 0.120 |
Why?
| | Electrocardiography | 1 | 2017 | 279 | 0.110 |
Why?
| | Drug Utilization | 1 | 2015 | 77 | 0.110 |
Why?
| | Coronary Angiography | 1 | 2017 | 384 | 0.110 |
Why?
| | Neoplasm Invasiveness | 1 | 2015 | 277 | 0.110 |
Why?
| | Tissue Plasminogen Activator | 1 | 2015 | 108 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2017 | 451 | 0.110 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 267 | 0.110 |
Why?
| | Survival Rate | 1 | 2017 | 945 | 0.110 |
Why?
| | Staphylococcus aureus | 1 | 2017 | 312 | 0.110 |
Why?
| | Echocardiography | 1 | 2017 | 415 | 0.110 |
Why?
| | Blood Pressure | 1 | 2016 | 535 | 0.100 |
Why?
| | Infusions, Intravenous | 1 | 2014 | 218 | 0.100 |
Why?
| | Antifungal Agents | 1 | 2016 | 346 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2017 | 630 | 0.100 |
Why?
| | Blood Loss, Surgical | 1 | 2013 | 69 | 0.100 |
Why?
| | Age Factors | 1 | 2016 | 1125 | 0.100 |
Why?
| | Thoracostomy | 1 | 2012 | 10 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2015 | 975 | 0.100 |
Why?
| | Chest Tubes | 1 | 2012 | 20 | 0.100 |
Why?
| | Preoperative Care | 1 | 2013 | 174 | 0.090 |
Why?
| | Hospitalization | 1 | 2017 | 739 | 0.090 |
Why?
| | Risk Assessment | 1 | 2016 | 1339 | 0.090 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 384 | 0.090 |
Why?
| | Cohort Studies | 1 | 2015 | 1541 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2017 | 1071 | 0.080 |
Why?
| | Cronobacter sakazakii | 1 | 2009 | 5 | 0.080 |
Why?
| | Enterobacteriaceae Infections | 1 | 2009 | 18 | 0.070 |
Why?
| | Osteomyelitis | 1 | 2009 | 125 | 0.070 |
Why?
| | Fluoroscopy | 1 | 2025 | 51 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2025 | 160 | 0.050 |
Why?
| | Adolescent | 1 | 2015 | 6681 | 0.050 |
Why?
| | Polymyxin B | 1 | 2023 | 4 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 120 | 0.050 |
Why?
| | Dogs | 1 | 2022 | 182 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2019 | 2282 | 0.050 |
Why?
| | Research Design | 1 | 2023 | 367 | 0.040 |
Why?
| | Multiple Myeloma | 1 | 2015 | 2999 | 0.040 |
Why?
| | Systole | 1 | 2019 | 74 | 0.040 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2019 | 54 | 0.040 |
Why?
| | Education, Medical | 1 | 2020 | 110 | 0.040 |
Why?
| | Cardiac Catheterization | 1 | 2019 | 241 | 0.030 |
Why?
| | Serratia marcescens | 1 | 2017 | 8 | 0.030 |
Why?
| | Arkansas | 2 | 2016 | 2016 | 0.030 |
Why?
| | Piperacillin | 1 | 2016 | 24 | 0.030 |
Why?
| | Prosthesis Failure | 1 | 2016 | 112 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2016 | 260 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 125 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2013 | 7 | 0.030 |
Why?
| | Dilatation | 1 | 2013 | 25 | 0.030 |
Why?
| | Length of Stay | 1 | 2016 | 666 | 0.030 |
Why?
| | Patient Safety | 1 | 2013 | 102 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 1193 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 2093 | 0.020 |
Why?
| | Discitis | 1 | 2009 | 10 | 0.020 |
Why?
| | Animals | 1 | 2022 | 13332 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2009 | 1518 | 0.010 |
Why?
|
|
Meena's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|